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Graphical abstract 
Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of tibolone 
on plasma fibrinogen (left panel) and ATP III (right panel) concentrations. Lower plot shows leave-one-
out sensitivity analysis. 
 
 
 
ABSTRACT:  
 
Tibolone is a synthetic steroid with estrogenic, androgenic and progestogenic activity, but the 
evidence regarding its effects on fibrinogen and anti-thrombin III (ATIII) has not been 
conclusive. We assessed the impact of tibolone on fibrinogen and ATIII through a systematic 
review and meta-analysis of available randomized controlled trials (RCTs). The search included 
PUBMED, Web of Science, Scopus, and Google Scholar (up to January 31st, 2016) to identify 
controlled clinical studies investigating the effects of oral tibolone treatment on fibrinogen and 
ATIII. Overall, the impact of tibolone on plasma fibrinogen concentrations was reported in 10 
trials comprising 11 treatment arms. Meta-analysis did not suggest a significant reduction of 
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fibrinogen levels following treatment with tibolone (WMD: -5.38%, 95% CI: -11.92, +1.16, p = 
0.107). This result was robust in the sensitivity analysis and not influenced after omitting each of 
the included studies from meta-analysis. When the studies were categorized according to the 
duration of treatment, there was no effect in the subsets of trials lasting either < 12 months 
(WMD: -7.64%, 95% CI: -16.58, +1.29, p = 0.094) or ≥ 12 months (WMD: -0.62%, 95% CI: -
8.40, +7.17, p = 0.876). With regard to ATIII, there was no change following treatment with 
tibolone (WMD: +0.74%, 95% CI: -1.44, +2.93, p = 0.505) and this effect was robust in 
sensitivity analysis. There was no differential effect of tibolone on plasma ATIII concentrations 
in trials with either < 12 months (WMD: +2.26%, 95% CI: -3.14, +7.66, p = 0.411) or ≥ 12 
months (WMD: +0.06%, 95% CI: -1.16, +1.28, p = 0.926) duration. Consistent with the results 
of subgroup analysis, meta-regression did not suggest any significant association between the 
changes in plasma concentrations of fibrinogen (slope: +0.40; 95% CI: -0.39, +1.19; p = 0.317) 
and ATIII (slope: -0.17; 95% CI: -0.54, +0.20; p = 0.374) with duration of treatment. In 
conclusion, meta-analysis did not suggest a significant reduction of fibrinogen and ATIII levels 
following treatment with tibolone.  
 
Key words: anti-thrombin III, fibrinogen, postmenopausal women, tibolone.  
 
No of words: 323 
 
INTRODUCTION 
Several studies found association between elevated plasma fibrinogen levels and 
cardiovascular disease (CVD) (1-3). Fibrinogen is one of the most important nontraditional CV 
risk factors (3-8). Associations of fibrinogen levels and coronary artery disease (CAD) or stroke 
were not dependent on sex, smoking, blood pressure or blood lipid levels (2). However, 
measurement of plasma fibrinogen to improve the prediction of CV risk is not recommended (7). 
Anti-thrombin III (ATIII) represents a major physiological inhibitor of thrombin activity in 
circulating blood (9). Low ATIII activity levels have been linked to elevated CV risk (10-12), 
and its deficiency, a genetically determined severe thrombophilic state, is associated with 
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markedly increased risk of venous thromboembolism (13,14), however this abnormality may 
also predispose to arterial thromboembolic events, including stroke, at young age (15). 
The incidence of CVD increases in women after menopause being a leading cause of 
mortality in postmenopausal women (16, 17). Menopause is associated with sex hormone 
deficiency and pro-atherogenic lipid profile changes including increase in total cholesterol and 
low density lipoprotein cholesterol (LDL-C) (18). Although observational studies had suggested 
some benefits with hormone replacement therapy (HRT) (19-21), randomized controlled trials 
(RCTs) failed to confirm it in terms of CV and thromboembolic risks (22, 23).  
Tibolone (Livial©, Tibofem©) is a synthetic steroid exhibiting estrogenic, progestogenic 
and androgenic activity. Its two major active metabolites - 3α- and 3β-hydroxytibolone - act as 
potent, fully activating agonists of the estrogen receptor, and its metabolite Δ4-tibolone act 
as agonist of the progesterone and androgen receptors (3α- and 3β hydroxytibolone conversely, 
act as antagonists of the same receptors). Moreover, tibolone acts as an antagonist of 
the glucocorticoid and mineralocorticoid receptors (24-27). Tibolone represents an attractive 
treatment option in postmenopausal women (24, 25) that effectively can reduce menopausal 
symptoms (24, 26, 27). At present tibolone is recommended as an alternative to menopausal 
hormone therapy in women with climacteric symptoms and no history of breast cancer and no 
other contraindications (28) especially in women with mood disorders and sexual dysfunction 
(29) and those with a history of endometriosis (30). A systematic review by Formoso et al. did 
not yield conclusive results regarding effect of tibolone on CV events (26). In the analyses of 
surrogate endpoints tibolone was reported to have various CV effects, including favourable 
effect on acute myocardial infarction and thromboembolism (24, 31, 32). Available data on 
tibolone-induced alterations to coagulation parameters were inconsistent (27, 31, 33). Previous 
studies reported reductions of fibrinogen level (8) or increase in ATIII level (27), while other 
investigators suggested procoagulant effects through lower ATIII levels (8, 34) or no change (31, 
35). Therefore the aim of the present study was to assess the impact of tibolone on fibrinogen 
and ATIII levels.  
 
METHODS  
Search Strategy 
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This study was designed according to the guidelines of the 2009 preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) statement (36). SCOPUS 
(http://www.scopus.com), Medline (http://www.ncbi.nlm.nih.gov/pubmed) AND Google Scholar 
(http://www.scholar.google.com) databases were searched using the following search terms in 
titles and abstracts (also in combination with MESH terms): (tibolone OR OrgOD14 OR “Org 
OD14” OR livial OR livial®) AND (fibrinogen OR antithrombin OR antithrombin III or 
“antithrombin III” OR ATIII OR “AT III”)). The wild-card term ‘‘*’’ was used to increase the 
sensitivity of the search strategy. No language restriction was used in the literature search. The 
search was limited to studies in human. The literature was searched from inception to January 
31st, 2016. 
  
Study Selection 
Original studies were included if they met the following inclusion criteria: (i) being a 
controlled clinical trial with either parallel or cross-over design, (ii) investigating the impact of 
tibolone on plasma concentrations of fibrinogen and/or ATIII, (iii) presentation of sufficient data 
on fibrinogen and/or ATIII concentrations at baseline and at the end of follow-up in each group 
or providing the net change values. Exclusion criteria were (i) lack of a an appropriate control 
group in the study design, (ii)observational studies with case-control, cross-sectional or cohort 
design, and (iii) lack of sufficient information on baseline or follow-up fibrinogen and/or ATIII 
concentrations.  
 
Data extraction  
Eligible studies were reviewed and the following data were abstracted: 1) first author's 
name; 2) year of publication; 3) study location; 4) study design; 5) number of participants in the 
tibolone and control groups; 5) age and body mass index (BMI) of study participants; 6) 
prevalence of diabetes mellitus; and 7) baseline and follow-up plasma concentrations of 
fibrinogen and/or ATIII. 
Quality assessment 
A systematic assessment of bias in the included studies was performed using the Cochrane 
criteria (37). The items used for the assessment of each study were as follows: adequacy of 
sequence generation, allocation concealment, blinding of subjects and personnel, blinding of 
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outcome assessment, addressing of dropouts (incomplete outcome data), selective outcome 
reporting, and other potential sources of bias. According to the recommendations of the 
Cochrane Handbook, a judgment of “yes” indicated low risk of bias, while “no” indicated high 
risk of bias. Labeling an item as “unclear” indicated an unclear or unknown risk of bias. 
  
Quantitative Data Synthesis 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software 
(Biostat, NJ) (38). Net changes in measurements (change scores) were calculated as follows: 
measure at end of follow-up − measure at baseline. For cross-over trials, net change in plasma 
concentrations of fibrinogen and/or ATIII were calculated by subtracting the value after control 
intervention from that reported after treatment. All values were collated in percentage changes 
from baseline levels. Standard deviations (SDs) of the mean difference were calculated using the 
following formula: SD = square root [(SDpre-treatment)
2 + (SDpost-treatment)
2 – (2R × SDpre-treatment × 
SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. If the outcome measures were 
reported in median and inter-quartile range, mean and standard SD values were estimated using 
the method described by Hozo et al. (39). Where standard error of the mean (SEM) was only 
reported, standard deviation (SD) was estimated using the following formula: SD = SEM × sqrt 
(n), where n is the number of subjects. When the results were presented in multiple time points, 
only data relating to the longest duration of treatment were considered. 
A random-effects model (using DerSimonian-Laird method) and the generic inverse 
variance method were used to compensate for the heterogeneity of studies in terms of 
demographic characteristics of populations being studied and also differences in study design. 
Heterogeneity was quantitatively assessed using I2 index. Effect sizes were expressed as 
weighted mean difference (WMD) and 95% confidence interval (CI). In order to evaluate the 
influence of each study on the overall effect size, sensitivity analysis was conducted using leave-
one-out method, i.e. removing one study each time and repeating the analysis. 
 
Meta-regression 
Random-effects meta-regression was performed using unrestricted maximum likelihood 
method to evaluate the association between calculated WMD and duration of treatment as a 
potential moderator. 
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Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel plot 
asymmetry, and Begg’s rank correlation and Egger’s weighted regression tests. Duval &Tweedie 
“trim and fill”method was used to adjust the analysis for the effects of publication bias (40). 
 
RESULTS 
Multidatabase search provided 64 articles. Of those, 51 were excluded after initial screening 
and the remaining 13 full text papers were reviewed. Finally, 12 were scrutinized as full texts 
and were selected to be included in the analysis (32, 35, 41-50). One article was excluded 
because of incomplete data (Figure 1). 
In total, 459 participants were allocated to tibolone supplementation group and 382 to 
control group in the selected studies. The number of participants in the analyzed studies ranged 
from 19 to 90 in the tibolone group and from 11 to 88 in the control group. They were published 
between 1987 and 2011, and were conducted in Turkey (3), Serbia (2), Greece, Italy, Korea, the 
Netherlands, Spain, Switzerland and UK. A range of tibolone doses from 1.25 to 2.5 mg/day was 
administered in the included trials. Duration of supplementation with tibolone ranged between 2 
and 24 months. Tibolone was safe and well-tolerated in all included studies with no report of any 
drug-related adverse events. Demographic and baseline parameters of the included studies are 
shown in Table 1.  
 
Risk of bias assessment 
In the majority of studies an unclear or high risk of bias with respect to sequence generation, 
allocation concealment and selective outcome reporting. Some studies were not randomized, nor 
blinded. The systematic assessment of bias in the included studies is presented in Table 2. 
 
Effect of tibolone on plasma fibrinogen concentrations 
Overall, the impact of tibolone on plasma fibrinogen concentrations was reported in 10 trials 
comprising 11 treatment arms. Meta-analysis did not suggest a significant reduction of 
fibrinogen levels following treatment with tibolone (WMD: -5.38%, 95% CI: -11.92, +1.16, p= 
0.107; I2=91.08%). This result was robust in the sensitivity analysis and not influenced after 
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omitting each of the included studies from meta-analysis (Figure 2). When the studies were 
categorized according to the duration of treatment, there was no effect in the subsets of trials 
lasting either < 12 months (WMD: -7.64%, 95% CI: -16.58, +1.29, p= 0.094; I2=94.33%) or ≥ 12 
months (WMD: -0.62%, 95% CI: -8.40, +7.17, p= 0.876; I2=51.88%) (Figure 3). 
There was no change in plasma ATIII following treatment with tibolone (WMD: +0.74%, 
95% CI: -1.44, +2.93, p= 0.505; I2=78.92%) and this effect was robust in sensitivity analysis 
(Figure 4). There was no differential effect of tibolone on plasma ATIII concentrations in trials 
with either < 12 months (WMD: +2.26%, 95% CI: -3.14, +7.66, p= 0.411; I2=88.20%) or ≥ 12 
months (WMD: +0.06%, 95% CI: -1.16, +1.28, p= 0.926; I2=3.13%) duration (Figure 5). 
 
Meta-regression 
Random-effects meta-regression was performed to assess if the changes in fibrinogen and 
ATIII are associated with duration of treatment. Consistent with the results of subgroup analysis, 
meta-regression did not suggest any significant association between the changes in plasma 
concentrations of fibrinogen (slope: +0.40; 95% CI: -0.39, +1.19; p = 0.317) and ATIII (slope: -
0.17; 95% CI: -0.54, +0.20; p = 0.374) with duration of treatment (Figure 6).  
 
Publication bias  
The funnel plot of the study standard error by effect size (WMD) was symmetric, suggesting 
lack of publication bias in the analysis of tibolone’s effect on plasma ATIII concentrations. This 
finding was confirmed by the results of Egger’s linear regression (intercept = 0.87, standard error 
= 0.93; 95% CI = -1.24, 2.98, t = 0.94, df = 9, two-tailed p = 0.374) and Begg’s rank correlation 
tests (Kendall’s Tau with continuity correction = 0.04, z = 0.16, two-tailed p-value = 0.876) 
(Figure 7). With regard to fibrinogen, visual inspection of funnel plot suggested a slight 
asymmetry that was imputed by two potentially missing studies on the left side of plot using 
“trim and fill “method (imputed WMD: -7.88%; 95% CI = -14.53, -1.23). In spite of this 
asymmetry, there was no sign of publication bias according to Egger’s linear regression 
(intercept = -2.23, standard error = 1.22; 95% CI = -4.98, 0.53, t = 1.83, df = 9, two-tailed p = 
0.101) and Begg’s rank correlation tests (Kendall’s Tau with continuity correction = -0.04, z = 
0.16, two-tailed p-value = 0.876). 
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DISCUSSION 
 The present meta-analysis of the data from 12 controlled trials including 841 patients has not 
revealed any significant alterations in the levels of two key coagulation proteins, i.e. fibrinogen 
and ATIII following treatment with tibolone in postmenopausal women. Our meta-analysis 
provided new information on the effects of tibolone on fibrinogen and ATIII, indicating that 
these two variables did not contribute to cardiovascular and thrombotic risks in women receiving 
tibolone. This observation might suggest that this form of therapy is neutral in terms of the 
occurrence of thromboembolic events, which are increasingly observed after menopause 
especially during combined hormone replacement therapy. 
 Tibolone was reported to have various CV effects (31). So far beneficial effect of tibolone 
was shown with respect to vasodilation, due to its estrogenic activity (24), and blood pressure 
(32). However it has also been shown to change lipid profile – due to its androgenic activity (24) 
– reductions of HDL cholesterol level were observed  (27, 33, 51), lower triglyceride levels were 
also reported (27, 51). On the other hand tibolone was also shown to reduce lipoprotein(a) levels, 
an independent risk factor for CVD in postmenopausal women (52).  
 In the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) trial tibolone effect 
on progression of atherosclerosis evaluated with carotid intima media thickness was assessed 
against continuous combined conjugated equine oestrogens plus medoxyprogesterone acetate 
and it was found that both active treatments were associated with increased progression as 
compared with placebo (53). Studies with clinical endpoint brought concern regarding tibolone 
use in older postmenopausal women. LIFT trial, which evaluated tibolone against placebo in 
older postmenopausal women was stopped early due to observed increased risk of stroke (6), but 
this finding was not confirmed in randomized controlled trial including younger women (54). 
Cochrane systematic review found higher risk of cerebrovascular events mainly due to results of 
abovementioned LIFT study and have not found significant differences in the risk of coronary 
heart disease, but since more cases were observed in tibolone than placebo group, it concluded 
that there was a trend toward increase of risk with the drug (26).  
 There is evidence of beneficial effect of tibolone on bone loss and risk of fractures (26, 55), 
incidence of vaginal bleeding in comparison with traditional hormone replacement therapy (26) 
and risk of invasive breast cancer in women without breast cancer history (5, 6), but not in 
women with breast cancer history (54). Therefore it is currently recommended by the Endocrine 
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Society as an alternative to menopausal hormone therapy in women with climacteric symptoms 
and no history of breast cancer and no other contraindications (28).  
 Our meta-analysis has strengths and limitations. Strength of present meta-analysis include 
extensive literature search including three databases without any language restrictions. The aim 
of nine of the studies was to measure the effect of tibolone on several markers, including two 
hemostasis markers assessed in present meta-analysis, so their aims were consistent with aims of 
our analysis. The risk of bias was performed in all included studies in accordance with Cochrane 
Risk of Bias Tool (37). The robustness of our results was checked using leave-one-out sensitivity 
analyses and heterogeneity was explored using both subgroup analyses and meta-regression. 
 The present meta-analysis also has several limitations. All the included studies had surrogate 
endpoints and assessed the effect of tibolone in comparison with placebo or no treatment; they 
also included estrogen only or estrogen/progestogen therapy group. Included studies used 
different assays for determination of fibrinogen and ATIII levels. None of the studies assessed 
any long-term cardiovascular or thrombotic outcomes. Most of the studies were of unclear or 
high risk of bias in more than one domain, especially with regard to randomization, which was 
not done or not properly reported in most of the studies. Unclear or inadequate sequence 
generation; allocation concealment is associated with overestimation of treatment effect (37, 56). 
Lack of blinding may also have an effect on the estimation of treatment effect (56), however it is 
believed to be less evident in case of objective outcomes (17, 57), such as laboratory measures, 
which were used in all the studies included in the meta-analysis. Regarding the influence of 
commercial funding bias (34) only four studies provided information about funding. So, overall 
quality of evidence on the effect of tibolone on fibrinogen and ATIII is low. Another limitation 
of our study is that we have not searched for unpublished studies, which may have introduced 
publication bias (8), however analyses of publication bias suggested no presence of such bias for 
ATIII level and slight asymmetry for fibrinogen level analyses.   
 Observed non-significant difference in fibrinogen and ATIII level changes after tibolone 
treatment as compared with placebo suggest no increase or decrease in cardiovascular risk 
attributed to those factors. In order to find out what is overall tibolone effect it would be 
necessary to evaluate its effect on all cardiovascular risk factors and on cardiovascular events.  
 In conclusion present meta-analysis revealed no consistent increase or decrease of 
fibrinogen or ATIII levels, however those results should be viewed cautiously because of high or 
11 
 
unclear risk of bias in the included studies. Use of tibolone requires careful assessment of risks 
and benefits of this therapy.  
 
CONFLICT OF INTEREST:  
 
Funding. This meta-analysis was written independently; no company or institution supported it 
financially.  
Declaration of interest: All the authors have nothing to declare. No professional writer was involved in 
the preparation of this meta-analysis. The meta-analysis has been prepared within the Lipid and Blood 
Pressure Meta-analysis Collaboration (LBPMC) Group (www.lbpmcgroup.umed.pl).  
 
 
ACKNOWLEDGMENTS:  
This meta-analysis was written independently; no company or institution supported it financially. 
No professional writer was involved in the preparation of this meta-analysis. The meta-analysis 
has been prepared within the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) 
Group (www.lbpmcgroup.umed.pl). 
 
12 
 
REFERENCES:  
1. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, et al. Association of 
fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring 
Population. Circulation. 2000;102(14):1634-8. 
2. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen 
level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant 
meta-analysis. Jama. 2005;294(14):1799-809. 
3. Kannel WB, Wolf PA, Castelli WP, D’agostino RB. Fibrinogen and Risk of Cardiovascular 
Disease: The Framingham Study. JAMA: The Journal of the American Medical Association. 
1987;258(9):1183-6. 
4. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting 
factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. The 
Lancet. 1993;342(8879):1076-9. 
5. Tabakci MM, Gerin F, Sunbul M, Toprak C, Durmus HI, Demir S, et al. Relation of Plasma 
Fibrinogen Level With the Presence, Severity, and Complexity of Coronary Artery Disease. Clin Appl 
Thromb Hemost. 2016. 
6. Kurtul A, Yarlioglues M, Murat SN, Duran M, Oksuz F, Koseoglu C, et al. The association of 
plasma fibrinogen with extent and complexity of coronary lesions in patients with acute coronary 
syndrome. Kardiol Pol. 2015. 
7. Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, et al. 
National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging 
biomarkers for primary prevention of cardiovascular disease. Clinical chemistry. 2009;55(2):378-84. 
8. Norris LA, Joyce M, O'Keeffe N, Sheppard BL, Bonnar J. Haemostatic risk factors in healthy 
postmenopausal women taking hormone replacement therapy. Maturitas. 2002;43(2):125-33. 
9. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia : the official 
journal of the World Federation of Hemophilia. 2008;14(6):1229-39. 
10. Pelkonen KM, Wartiovaara-Kautto U, Nieminen MS, Ahonen K, Sinisalo J. Low normal level of 
protein C or of antithrombin increases risk for recurrent cardiovascular events. Blood coagulation & 
fibrinolysis : an international journal in haemostasis and thrombosis. 2005;16(4):275-80. 
11. Thompson SG, Fechtrup C, Squire E, Heyse U, Breithardt G, van de Loo JC, et al. Antithrombin 
III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arteriosclerosis, 
thrombosis, and vascular biology. 1996;16(3):357-62. 
12. Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. 
Lancet (London, England). 1991;338(8771):850-1. 
13 
 
13. Collaboration TERF. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. 
New England Journal of Medicine. 2012;367(14):1310-20. 
14. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk 
of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone 
replacement therapy. Thrombosis and Haemostasis. 2000;83(4):530-5. 
15. Szymanska M, Alhenc-Gelas M, Undas A. Recurrent ischemic cerebrovascular events in a patient 
with type I antithrombin deficiency caused by 9788 G>A splice site mutation: a case report. Blood 
coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2013;24(2):213-5. 
16. Maas A, Appelman Y. Gender differences in coronary heart disease. Neth Heart J. 
2010;18(12):598-602. 
17. Vitale C, Miceli M, Rosano GM. Gender-specific characteristics of atherosclerosis in menopausal 
women: risk factors, clinical course and strategies for prevention. Climacteric : the journal of the 
International Menopause Society. 2007;10 Suppl 2:16-20. 
18. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and 
lipoproteins in healthy women. Atherosclerosis. 1993;98(1):83-90. 
19. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal 
estrogen and progestin use and the risk of cardiovascular disease. The New England journal of medicine. 
1996;335(7):453-61. 
20. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, 
observational study of postmenopausal hormone therapy and primary prevention of cardiovascular 
disease. Annals of internal medicine. 2000;133(12):933-41. 
21. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal 
estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. The New 
England journal of medicine. 1991;325(11):756-62. 
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of 
estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. 
Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama. 1998;280(7):605-13. 
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks 
and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the 
Women's Health Initiative randomized controlled trial. Jama. 2002;288(3):321-33. 
24. Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas. 1998;30(3):295-305. 
25. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of 
the International Tibolone Consensus Group. Maturitas. 2005;51(1):21-8. 
14 
 
26. Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, et al. Short and long term 
effects of tibolone in postmenopausal women. The Cochrane database of systematic reviews. 
2012;2:Cd008536. 
27. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of 
randomized trials. The Journal of clinical endocrinology and metabolism. 2002;87(1):16-23. 
28. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of 
Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. The Journal of clinical 
endocrinology and metabolism. 2015;100(11):3975-4011. 
29. Blumel JE, Aravena H, Brantes S, Cruzat L, Lavin P, Montano R, et al. [Official position of the 
Chilean Society of Climacteric on the management of climacteric women]. Revista medica de Chile. 
2010;138(5):645-51. 
30. Moen MH, Rees M, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, et al. EMAS position 
statement: Managing the menopause in women with a past history of endometriosis. Maturitas. 
2010;67(1):94-7. 
31. Campisi R, Marengo FD. Cardiovascular effects of tibolone: a selective tissue estrogenic activity 
regulator. Cardiovascular drug reviews. 2007;25(2):132-45. 
32. Lloyd G, McGing E, Cooper A, Patel N, Lumb PJ, Wierzbicki AS, et al. A randomised placebo 
controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. Journal of 
human hypertension. 2000;14(2):99-104. 
33. Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on 
recent randomised controlled clinical trials. Gynecological endocrinology : the official journal of the 
International Society of Gynecological Endocrinology. 2010;26(11):804-14. 
34. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential 
effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation 
and fibrinolysis. Thrombosis Research. 2007;120(3):371-9. 
35. Koh KK, Ahn JY, Jin DK, Yoon BK, Kim HS, Kim DS, et al. Significant differential effects of 
hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a 
randomized, double-blind, placebo-controlled, crossover study. Arteriosclerosis, thrombosis, and vascular 
biology. 2003;23(10):1889-94. 
36. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535. 
37. Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated 
March 2011]. The Cochrane Collaboration. 2011. 
15 
 
38. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 2. 
Englewood, NJ: Biostat. 2005:104-. 
39. Hozo S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and 
the size of a sample. BMC Medical Research Methodology. 2005;5(1):1-10. 
40. Duval S, Tweedie R. Trim and fill: a simple funnel‐ plot–based method of testing and adjusting 
for publication bias in meta‐ analysis. Biometrics. 2000;56(2):455-63. 
41. Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on 
markers of cardiovascular disease. The Journal of clinical endocrinology and metabolism. 
1997;82(6):1752-6. 
42. Sarac F, Saydam G, Sahin F, Oztekin K, Saygili F, Tuzun M, et al. Effects of hormone 
replacement therapy on insulin resistance and platelet function tests. Medical principles and practice : 
international journal of the Kuwait University, Health Science Centre. 2009;18(1):43-7. 
43. Jeremic K, Lazovic G, Tulic I, Gojnic M, Stojnic J, Jeremic J. [Effects of tibolone on the risk 
factors for cardiovascular diseases in postmenopausal women]. Vojnosanitetski pregled. 2006;63(4):387-
91. 
44. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, Okumus B, Bozkaya H. Effect of 
different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone 
mineral density in overweight and obese postmenopausal women. Fertility and sterility. 2005;84(2):384-
93. 
45. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. 
Maturitas. 1987;Suppl 1:67-72. 
46. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH. Long-term influence of different 
postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. 
British journal of obstetrics and gynaecology. 1997;104(6):708-17. 
47. Perrone G, Capri O, Galoppi P, Brunelli R, Bevilacqua E, Ceci F, et al. Effects of either tibolone 
or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors 
and lipoprotein(a) in menopause. Gynecologic and obstetric investigation. 2009;68(1):33-9. 
48. Demirol A, Guven S, Guvendag Guven ES, Kirazli S, Gurgan T, Ayhan A. Comparison of the 
effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-
blind, placebo-controlled study. Fertility and sterility. 2007;87(4):842-8. 
49. Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis 
J, et al. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in 
postmenopausal women. Climacteric : the journal of the International Menopause Society. 
2007;10(5):400-7. 
16 
 
50. Tasic L, Dunjic R, Vasiljevic M, Dikic S, Jurisic A, Tasic D. [Comparison of two different types 
of hormone therapy effects on haemostatic parameters in early postmenopausal women]. Srpski arhiv za 
celokupno lekarstvo. 2011;139(1-2):52-7. 
51. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and 
apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertility and sterility. 
2001;75(5):898-915. 
52. Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, et al. Tibolone decreases 
Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies 
with 1009 patients. Atherosclerosis. 2015;242(1):87-96. 
53. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, et al. The effect of 
tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on 
progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of 
tiboLone (OPAL) study. European heart journal. 2006;27(6):746-55. 
54. Kenemans P, Bundred NJ, Foidart J-M, Kubista E, von Schoultz B, Sismondi P, et al. Safety and 
efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-
inferiority trial. The Lancet Oncology. 2009;10(2):135-46. 
55. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The 
effects of tibolone in older postmenopausal women. The New England journal of medicine. 
2008;359(7):697-708. 
56. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study 
design characteristics on intervention effect estimates from randomized, controlled trials. Annals of 
internal medicine. 2012;157(6):429-38. 
57. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in 
treatment effect estimates in controlled trials with different interventions and outcomes: meta-
epidemiological study. BMJ (Clinical research ed). 2008;336(7644):601-5. 
 
17 
 
 
FIGURE LEGENDS  
Figure 1. Flow chart 
of the number of studies identiﬁed and included into the meta-analysis.   
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Figure 2. 
Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of 
tibolone on plasma fibrinogen concentrations. Lower plot shows leave-one-out sensitivity 
analysis. 
19 
 
Figure 3. Forest 
plot displaying weighted mean difference and 95% confidence intervals for the impact of 
tibolone on plasma fibrinogen concentrations in trials lasting < 12 months (upper plot) and ≥ 12 
months (lower plot).  
20 
 
Figure 4. Forest 
plot displaying weighted mean difference and 95% confidence intervals for the impact of 
tibolone on plasma ATIII concentrations. Lower plot shows leave-one-out sensitivity analysis. 
Figure 5. Forest plot 
displaying weighted mean difference and 95% confidence intervals for the impact of tibolone on 
plasma ATIII concentrations in trials lasting < 12 months (upper plot) and ≥ 12 months (lower 
plot).  
21 
 
Figure 6. Meta-regression plots of the association between mean changes in plasma fibrinogen 
(upper plot) and ATIII (lower plot) concentrations with duration of treatment with tibolone. The 
size of each circle is inversely proportional to the variance of change. 
22 
 
Figur
e 7. Funnel plot detailing publication bias in the studies reporting the impact of tibolone on 
plasma fibrinogen (upper plot) and ATIII (lower plot) concentrations. Open diamond represents 
observed effect size; closed diamond represents imputed effect size. 
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Table 2. Risk of bias assessment in the studies considered for meta-analysis.  
 
Study Ref Sequence 
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) 
U U L L L L U 
Sarac et al.  (42
) 
H H U U L L L 
Jeremic et al.  (43
) 
H H U U L L L 
Koh et al.  (35
) 
U U U L L L L  
Osmanagaogl
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(44
) 
L U U U L L L 
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) 
U U U U L L L 
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) 
H H L L L L L 
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) 
U U L L L L H 
Perrone et al.  (47
) 
U U U U H L L  
Demirol et al.  (48
) 
U U L L L L L 
Keramaris et 
al.  
(49
) 
H H U U H L L  
Tasic et al.  (50
) 
U U U U L L L 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias 
 
 
